SCHEMBL6242534

SCHEMBL6242534

Brc1ccc(-c2cc(Nc3ccccc3)n[nH]2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.65
CDK1 P06493 2/20 0.65
CHEK1 O14757 1/20 0.63
TNIK Q9UKE5 6/20 0.60
ALDH1A1 P00352 3/20 0.54
GAA P10253 2/20 0.54
MAPT P10636 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
HSD17B10 Q99714 1/20 0.54
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
STAT1 P42224 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
USP2 O75604 1/20 0.50
GAK O14976 1/20 0.48
PDGFRB P09619 1/20 0.48
KIT P10721 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18434151 0.89 CHEK1 (0.67) CDK2CDK1CHEK1TNIKALDH1A1
SCHEMBL21262377 0.84 TNIK (0.83) CDK2CDK1CHEK1TNIKGAK
SCHEMBL21262705 0.82 TNIK (0.66) CDK2CDK1CHEK1TNIKALDH1A1
SCHEMBL21262430 0.82 CDK2 (0.67) CDK2CDK1CHEK1TNIKALDH1A1
SCHEMBL12524973 0.81 CHEK1 (0.62) CDK2CDK1CHEK1TNIKALDH1A1
SCHEMBL21262648 0.79 TNIK (0.85) CDK2CDK1CHEK1TNIKALDH1A1
SCHEMBL9820222 0.78 TNIK (0.85) CDK2CDK1CHEK1TNIKALDH1A1
SCHEMBL6241589 0.77 CHEK1 (1.00) CDK2CDK1CHEK1TNIK
SCHEMBL21247715 0.76 CDK2 (0.76) CDK2CDK1CHEK1TNIKALDH1A1
SCHEMBL21247516 0.76 TNIK (1.00) CDK1CHEK1TNIKGAKPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043381-A1 Aminopyrazole compounds AGOURON PHARMACEUTICALS, INC. 2005-02-24 US disclosed
WO-2005009435-A1 AMINOPYRAZOLE COMPOUNDS AND USE AS CHK1 INHIBITORS PFIZER INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043381-A1 Aminopyrazole compounds CDK1, CDK3, BUB1B CDK2 11/4885CDK1 1/4885CHEK1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.